QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:PTCT

PTC Therapeutics News Headlines

$37.93
+0.95 (+2.57%)
(As of 12/7/2021 04:00 PM ET)
Add
Compare
Today's Range
$37.49
$38.85
50-Day Range
$35.36
$41.59
52-Week Range
$34.85
$70.82
Volume
513,513 shs
Average Volume
508,579 shs
Market Capitalization
$2.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.89

Media Mentions By Week



PTC Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PTCT
News Sentiment

0.00

0.34

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PTCT Articles
This Week

0

1

PTCT Articles
Average Week

Get PTC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

PTC Therapeutics (NASDAQ:PTCT) News Headlines Today

SourceHeadline
MarketBeat logoPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up to $38.84
americanbankingnews.com - November 17 at 10:54 AM
finance.yahoo.com logoIs Therapeutics (NASDAQ:PTCT) Weighed On By Its Debt Load?
finance.yahoo.com - November 8 at 6:28 PM
MarketBeat logoPTC Therapeutics (NASDAQ:PTCT) PT Lowered to $55.00 at Raymond James
americanbankingnews.com - October 29 at 11:15 AM
finance.yahoo.com logoPTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results
finance.yahoo.com - October 28 at 5:57 PM
benzinga.com logoPTC Therapeutics Earnings Perspective: Return On Capital Employed
benzinga.com - October 28 at 12:57 PM
finance.yahoo.com logoWhere Do Hedge Funds Stand On PTC Therapeutics, Inc. (PTCT)?
finance.yahoo.com - October 25 at 10:11 PM
finance.yahoo.com logoPTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil
finance.yahoo.com - October 25 at 12:09 PM
finance.yahoo.com logoEarnings Preview: PTC Therapeutics (PTCT) Q3 Earnings Expected to Decline
finance.yahoo.com - October 21 at 7:45 PM
finance.yahoo.com logoPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results
finance.yahoo.com - October 14 at 1:26 PM
finance.yahoo.com logoTegsedi® Receives Innovative Drug Category Pricing in Brazil
finance.yahoo.com - October 11 at 8:53 AM
finance.yahoo.com logoThe Recent Pullback in These 2 Stocks Is a ‘Buying Opportunity,’ Say Analysts
finance.yahoo.com - October 6 at 8:23 PM
markets.businessinsider.com logoPTC : Results Show Improvements In Children With AADC Deficiency Treated With PTC-AADC Gene Therapy
markets.businessinsider.com - September 29 at 2:30 PM
finance.yahoo.com logoResults Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy
finance.yahoo.com - September 29 at 2:30 PM
finance.yahoo.com logoPTCT Oct 2021 35.000 put
finance.yahoo.com - September 26 at 11:04 PM
nasdaq.com logoInvestors in Therapeutics (NASDAQ:PTCT) have made a strong return of 242% over the past five years
nasdaq.com - September 24 at 1:43 PM
msn.com logoBRIEF-PTC Therapeutics Inc Data Show Translarna Delays Loss Of Ambulation By More Than Five Years
msn.com - September 20 at 7:00 PM
finance.yahoo.com logoPTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program
finance.yahoo.com - September 20 at 7:00 PM
finance.yahoo.com logoSTRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy
finance.yahoo.com - September 20 at 8:59 AM
finance.yahoo.com logoPTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community
finance.yahoo.com - September 7 at 8:36 AM
nasdaq.com logoFirst Week of PTCT October 15th Options Trading
nasdaq.com - August 30 at 3:43 PM
finance.yahoo.com logoPTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder
finance.yahoo.com - August 24 at 5:57 PM
finance.yahoo.com logoTargeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency
finance.yahoo.com - August 23 at 4:44 PM
finance.yahoo.com logoPTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome
finance.yahoo.com - August 23 at 4:44 PM
nasdaq.com logoThis Insider Has Just Sold Shares In PTC Therapeutics, Inc. (NASDAQ:PTCT)
nasdaq.com - August 19 at 8:14 AM
finance.yahoo.com logoInvesting in Therapeutics (NASDAQ:PTCT) five years ago would have delivered you a 385% gain
finance.yahoo.com - August 10 at 2:18 PM
nasdaq.com logoTherapeutics (NASDAQ:PTCT) Has Debt But No Earnings; Should You Worry?
nasdaq.com - August 5 at 1:56 PM
finance.yahoo.com logoPTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results
finance.yahoo.com - July 29 at 8:30 PM
finance.yahoo.com logoSignificant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™
finance.yahoo.com - July 28 at 6:17 PM
benzinga.com logoEarnings Outlook For PTC Therapeutics
benzinga.com - July 28 at 1:16 PM
nasdaq.com logoPTC Therapeutics, Inc. Common Stock (PTCT)
nasdaq.com - July 23 at 11:34 PM
nasdaq.com logoPTC Therapeutics, Inc. Common Stock (PTCT)
nasdaq.com - July 23 at 11:34 PM
finance.yahoo.com logoPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results
finance.yahoo.com - July 15 at 9:45 AM
finance.yahoo.com logoResults Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone
finance.yahoo.com - June 24 at 9:12 AM
markets.businessinsider.com logoPTC Therapeutics Says Evrysdi Approved In Japan To Treat Spinal Muscular Atrophy - Quick Facts
markets.businessinsider.com - June 23 at 12:20 PM
finance.yahoo.com logoA Look At The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)
finance.yahoo.com - June 11 at 12:51 PM
finance.yahoo.com logoPTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU
finance.yahoo.com - May 27 at 12:57 PM
finance.yahoo.com logoPTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia
finance.yahoo.com - May 26 at 9:55 AM
finance.yahoo.com logoPTC Therapeutics to Participate at Upcoming Virtual Investor Conference
finance.yahoo.com - May 19 at 11:07 AM
finanznachrichten.de logoPTC Therapeutics, Inc.: New Data Shows Devastating Impact of AADC Deficiency on Caregivers
finanznachrichten.de - May 17 at 9:54 AM
finance.yahoo.com logoNew Data Shows Devastating Impact of AADC Deficiency on Caregivers
finance.yahoo.com - May 17 at 9:54 AM
ca.finance.yahoo.com logoPTC Therapeutics Stock Appears To Be Modestly Undervalued
ca.finance.yahoo.com - May 7 at 10:35 AM
finance.yahoo.com logoPTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 4 at 11:03 PM
finance.yahoo.com logoPTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 4 at 6:03 PM
finance.yahoo.com logoPTC Therapeutics (PTCT) Enters Oversold Territory
finance.yahoo.com - April 30 at 9:44 AM
finance.yahoo.com logoIs PTCT Stock A Buy or Sell?
finance.yahoo.com - April 24 at 6:49 PM
nasdaq.com logoPTC Therapeutics Becomes Oversold (PTCT)
nasdaq.com - April 23 at 2:18 PM
finance.yahoo.com logoPTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results
finance.yahoo.com - April 20 at 12:22 PM
nasdaq.com logoRoche : Evrysdi Continues To Improve Motor Function And Survival In Infants With Type 1 SMA
nasdaq.com - April 15 at 8:21 AM
finance.yahoo.com logoContinued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™
finance.yahoo.com - April 15 at 1:40 AM
finance.yahoo.com logoPTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing
finance.yahoo.com - April 14 at 10:38 AM
Get PTC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.